According to the Complaint, it is alleged Defendants made false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding aducanumab's effectiveness; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the FDA's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Biogen Inc. Securities Litigation (2020)
Nov 17, 2020 | Biogen Inc. NASDAQ: BIIB | Case Status: Filed
If you purchased a significant amount of shares of Biogen Inc. (NASDAQ: BIIB), you have certain options. Investors should contact us.
Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Biogen Inc.
First Identified Complaint
Victor D. Menashe, et al. v. Biogen Inc., et al.
First Identified Complaint Filings
|#||Document Title||Filing Date|
|1||Class Action Complaint for Violation of the Securities Act of 1933||November 13th, 2020|
|2||U.S. District Court Civil Docket||November 13th, 2020|